<p>，/PRNewswire/ -- 上海证券交易所上市公司成都先导（&#34;成都先导&#34;，SSE: 688222.SH）于 2026 年 4 月 29 日发布了其《2025 年可持续发展报告》。该报告是成都先导的第二份可持续发展报告，旨在展示公司在环境、社会和治理（&#34;ESG&#34;）领域的理念和政策，以及其在 2025 年的可持续发展实践和表现，以系统性地回应利益相关者的关切。</p>
<p><strong>成都先导董事长兼首席执行官李进博士</strong> 评论道：&#34;作为一家致力于'为人类健康做贡献'的创新生物制药企业，成都先导始终相信公司的核心在于持续创造价值。在 2025 年，我们继续致力于务实和坚定的行动，将可持续发展融入战略，嵌入管理，深植于运营中。这为长期成功奠定了坚实的基础，使我们能够通过成都先导的切实努力，持续为我们的客户、合作伙伴、投资者、员工以及我们所依赖的环境和社区做出贡献。&#34;</p>
<ul>
<li><strong>可持续企业治理</strong></li>
</ul>
<p>成都先导持续优化其治理体系，秉持商业运营中的诚信原则，树立行业标杆，并建立全面的风险管理体系，以促进长期稳定的发展，为所有利益相关者创造可持续价值。</p>
<ul>
<li><strong>负责任的价值链</strong></li>
</ul>
<p>成都先导坚持产品安全和服务质量，构建可持续供应链，系统管理价值链的各个方面，致力于与利益相关者共同创造长期综合价值。</p>
<ul>
<li><strong>员工与社区</strong></li>
</ul>
<p>成都先导将员工视为可持续发展的核心驱动力，将社区视为共同成长的重要合作伙伴。坚持以人为本的责任理念，致力于回馈社会，成都先导促进员工成长和社区共同发展。</p>
<ul>
<li><strong>环境</strong></li>
</ul>
<p>成都先导坚持绿色发展的理念，将环境管理融入企业运营和发展战略，系统推进环境管理、生态保护、废物管理、资源利用、应对气候变化等各项举措。</p>
<p><strong>李进博士</strong> 表示：&#34;每一步都很重要，最终会走得很远。在我们成为世界级创新生物制药企业的旅程中，我们将继续以市场需求为导向，以技术突破为动力，不断优化我们的创新药物发现服务体系，为建设一个更具包容性、健康、绿色和可及的世界贡献力量。&#34;</p>
<p>有关成都先导可持续发展报告的更多信息，请访问：</p>
<p>https://www.hitgen.com/en/sustainability.html</p>
<p><strong>关于成都先导</strong></p>
<p>成都先导（SSE: 688222.SH）致力于建设一家世界级的创新生物制药企业。以推动人类健康和生活质量为使命，提供创新治疗解决方案以满足未被满足的医疗需求。公司以其国际领先的 DEL（DNA 编码库）技术为中心，扩展到基于片段的药物发现和基于结构的药物设计，以及基于寡核苷酸治疗、靶向接近药物和环肽模仿物的一系列互补平台，并开发了 HAILO，一个专有的&#34;DEL+AI+ 自动化&#34;分子优化平台，从而建立了一个独特的新型分子发现引擎，向全球制药行业提供治疗分子和工具分子。成都先导总部位于中国成都，在英国剑桥和美国休斯顿设有子公司，运营网络遍布全球。通过包括技术服务、项目外许可和产品销售在内的多样化和灵活的商业模式，公司与广泛的制药和生物技术公司、化学公司、基金会和研究机构建立了广泛的合作关系。截至 2025 年底，已为全球超过 600 个客户提供支持，并为他们的数千个创新药物开发项目做出贡献。成都先导还在多个临床和临床前阶段推进多个内部项目。有关更多信息，请访问 www.hitgen.com。</p>
<p>来源：成都先导</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDI5Jk5ld3NJdGVtSWQ9Q040NjQ5MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjkwNzAwUFJfTkVXU19VU1BSX19fX19DTjQ2NDkz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDI5Jk5ld3NJdGVtSWQ9Q040NjQ5MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjkwNzAwUFJfTkVXU19VU1BSX19fX19DTjQ2NDkz"/></p>

成都先导

<p>成都先导（SSE:）于 2026 年 4 月 29 日发布了 2025 年可持续发展报告。该报告概述了公司的 ESG 理念、可持续实践和业绩。首席执行官李进博士强调了将可持续发展融入战略和运营的重要性。成都先导专注于优化治理，确保产品安全，并促进员工和社区的成长。公司致力于绿色发展和应对气候变化。成都先导的目标是成为一家世界级的生物制药企业，利用创新技术提升人类健康和生活质量</p>

<p>, /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. (&#34;HitGen&#34;, SSE: 688222.SH) released its <em>2025 Sustainability Report</em> on April 29, 2026. This report is the second sustainability report of HitGen, aiming to present the Company's philosophies and policies in environmental, social, and governance (&#34;ESG&#34;) areas, as well as its sustainable development practices and performance in the year of 2025, to systematically respond to stakeholder concerns.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- 上海证券交易所上市公司成都先导（&#34;成都先导&#34;，SSE: 688222.SH）于 2026 年 4 月 29 日发布了其《2025 年可持续发展报告》。该报告是成都先导的第二份可持续发展报告，旨在展示公司在环境、社会和治理（&#34;ESG&#34;）领域的理念和政策，以及其在 2025 年的可持续发展实践和表现，以系统性地回应利益相关者的关切。</p>
</div><p><strong>Dr. Jin Li, Chairman of the Board and CEO of HitGen Inc.</strong>, commented: &#34;As an innovative biopharmaceutical enterprise committed to 'contributing to human health', HitGen has always believed that the core of a company lies in continuously creating value. In 2025, we remained dedicated to practical and determined actions, driving sustainable development to be integrated into strategy, embedded in management, and deeply rooted in operations. This strengthens the solid foundation for long-term success and enables us to continuously contribute, through tangible efforts from HitGen, to our customers, collaborators, investors, employees, as well as the environment and communities on which we depend.&#34;</p>
<div class="lb-trans"><p><strong>成都先导董事长兼首席执行官李进博士</strong> 评论道：&#34;作为一家致力于'为人类健康做贡献'的创新生物制药企业，成都先导始终相信公司的核心在于持续创造价值。在 2025 年，我们继续致力于务实和坚定的行动，将可持续发展融入战略，嵌入管理，深植于运营中。这为长期成功奠定了坚实的基础，使我们能够通过成都先导的切实努力，持续为我们的客户、合作伙伴、投资者、员工以及我们所依赖的环境和社区做出贡献。&#34;</p>
</div><ul>
<li><strong>Sustainable Corporate Governance</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>可持续企业治理</strong></li>
</ul>
</div><p>HitGen continuously optimizes its governance system, upholds the principle of integrity in business operations to set an industry benchmark, and establishes a comprehensive risk management system to promote long-term and stable development, creating sustainable value for all stakeholders.</p>
<div class="lb-trans"><p>成都先导持续优化其治理体系，秉持商业运营中的诚信原则，树立行业标杆，并建立全面的风险管理体系，以促进长期稳定的发展，为所有利益相关者创造可持续价值。</p>
</div><ul>
<li><strong>Responsible Value Chain</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>负责任的价值链</strong></li>
</ul>
</div><p>HitGen adheres to product safety and service quality, builds a sustainable supply chain, systematically manages all aspects of the value chain, and is committed to collaboratively creating long-term comprehensive value with stakeholders.</p>
<div class="lb-trans"><p>成都先导坚持产品安全和服务质量，构建可持续供应链，系统管理价值链的各个方面，致力于与利益相关者共同创造长期综合价值。</p>
</div><ul>
<li><strong>Employees and Community</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>员工与社区</strong></li>
</ul>
</div><p>HitGen regards employees as the core driving force for sustainable development and communities as important partners for mutual growth. Adhering to a responsibility philosophy centred on people and dedicated to giving back to society, HitGen promotes employee growth and community co-development.</p>
<div class="lb-trans"><p>成都先导将员工视为可持续发展的核心驱动力，将社区视为共同成长的重要合作伙伴。坚持以人为本的责任理念，致力于回馈社会，成都先导促进员工成长和社区共同发展。</p>
</div><ul>
<li><strong>Environment</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>环境</strong></li>
</ul>
</div><p>HitGen adheres to the concept of green development, integrates environmental management into corporate operation and development strategies, and systematically advances environmental management, ecological protection, waste management, resource utilization, addressing climate change and other initiatives.</p>
<div class="lb-trans"><p>成都先导坚持绿色发展的理念，将环境管理融入企业运营和发展战略，系统推进环境管理、生态保护、废物管理、资源利用、应对气候变化等各项举措。</p>
</div><p><strong>Dr. Jin Li</strong> said, &#34;Every step counts, leading to great distances. On our journey to becoming a world-class innovative biopharmaceutical enterprise, we will continue to adhere to market demand as our guide and technological breakthroughs as our engine, continuously optimizing our innovative drug discovery services system, and contributing to building a more inclusive, healthy, green and accessible world.&#34;</p>
<div class="lb-trans"><p><strong>李进博士</strong> 表示：&#34;每一步都很重要，最终会走得很远。在我们成为世界级创新生物制药企业的旅程中，我们将继续以市场需求为导向，以技术突破为动力，不断优化我们的创新药物发现服务体系，为建设一个更具包容性、健康、绿色和可及的世界贡献力量。&#34;</p>
</div><p>For more information on HitGen's Sustainability Report, please visit:</p>
<div class="lb-trans"><p>有关成都先导可持续发展报告的更多信息，请访问：</p>
</div><p>https://www.hitgen.com/en/sustainability.html</p>
<div class="lb-trans"><p>https://www.hitgen.com/en/sustainability.html</p>
</div><p><strong>About HitGen Inc.</strong></p>
<div class="lb-trans"><p><strong>关于成都先导</strong></p>
</div><p>HitGen Inc. (SSE: 688222.SH) is dedicated to building a world-class innovative biopharmaceutical enterprise. Driven by the mission to advance human health and quality of life, it provides innovative therapeutic solutions to address unmet medical needs. Centered on its internationally leading DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics, and has developed HAILO, a proprietary &#34;DEL+AI+Automation&#34; molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutics molecules and tool molecules to the global pharmaceutical industry. Headquartered in Chengdu, China, HitGen maintains subsidiaries in Cambridge, UK, and Houston, USA, with its operational network spanning the globe. Through diversified and flexible business models including technical services, project out-licensing and product sales, the Company has forged extensive collaborations with a broad range of pharmaceutical and biotechnology companies, chemical firms, foundations, and research institutions. As of the end of 2025, it has empowered over 600 clients globally and contributed to thousands of their innovative drug development projects. HitGen also advances multiple internal programmes at various clinical and preclinical stages. For more information, please visit www.hitgen.com.</p>
<div class="lb-trans"><p>成都先导（SSE: 688222.SH）致力于建设一家世界级的创新生物制药企业。以推动人类健康和生活质量为使命，提供创新治疗解决方案以满足未被满足的医疗需求。公司以其国际领先的 DEL（DNA 编码库）技术为中心，扩展到基于片段的药物发现和基于结构的药物设计，以及基于寡核苷酸治疗、靶向接近药物和环肽模仿物的一系列互补平台，并开发了 HAILO，一个专有的&#34;DEL+AI+ 自动化&#34;分子优化平台，从而建立了一个独特的新型分子发现引擎，向全球制药行业提供治疗分子和工具分子。成都先导总部位于中国成都，在英国剑桥和美国休斯顿设有子公司，运营网络遍布全球。通过包括技术服务、项目外许可和产品销售在内的多样化和灵活的商业模式，公司与广泛的制药和生物技术公司、化学公司、基金会和研究机构建立了广泛的合作关系。截至 2025 年底，已为全球超过 600 个客户提供支持，并为他们的数千个创新药物开发项目做出贡献。成都先导还在多个临床和临床前阶段推进多个内部项目。有关更多信息，请访问 www.hitgen.com。</p>
</div><p>SOURCE HitGen Inc.</p>
<div class="lb-trans"><p>来源：成都先导</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDI5Jk5ld3NJdGVtSWQ9Q040NjQ5MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjkwNzAwUFJfTkVXU19VU1BSX19fX19DTjQ2NDkz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN46493&amp;Transmission_Id=202604290700PR_NEWS_USPR_____CN46493&amp;DateId=20260429"/></p>

07:00 ETESG | 成都先导发布 2025 年可持续发展报告